Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Blauvelt, Andrew; Papp, Kim; Griffiths, C.E.M.; Randazzo, B.; Wasfi, Yasmine; Shen, Yaung‐Kaung; Li, Shu; B. Kimball, Alexa

doi:10.1016/j.jaad.2016.11.041

Public

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Published in Journal of the American Academy of Dermatology • Jan 4, 2017

Authors:

Andrew Blauvelt

Kim Papp

C.E.M. Griffiths

Abstract

BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. OBJECTIVES: We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis treated for 1 year. METHODS: Patients ...

Subject

Medicine

Psoriasis

Adalimumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!